User:Mac/Agenda: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
 
(11 intermediate revisions by the same user not shown)
Line 1: Line 1:
== 18 Jan 2010 ==
[[/18 Jan 2010|Notes]]
<strike>
* [[Diagnostic_Kits#Field_Definition|write 1 paragraph / section of paper outline (now in Field Definition)]]
</strike>
* track down a ton of papers from the bibliographies of ''Legal uncertainty in the area of genetic diagnostic testing'' and ''Genome patents and personalized medicine - what lies ahead?''
** add the above to the bibliography
* read chapter 20, ''Gene patents: from discovery to invention'' from ''Gene Patents and Collaborative Licensing Models''
** add the above to the bibliography
** [[Diagnostic_Kits/Genes_and_ingenuity:_gene_patenting_and_human_health_report|Australian Law Reform Commission. Genes and ingenuity: gene patenting and human health report.  (2004) pp. 678]]
** [[/Diagnostic_Kits/Patenting_and_licensing_in_genetic_testing:_recommendations_of_the_European_Society_of_Human_Genetics|Aymé et al. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics. European Journal of Human Genetics (2008) vol. 16 Suppl 1 pp. S10-9]]
* read a bunch of other papers I printed
* compress the findings of the SACGHS report, European report, and Australian report in an executive summary in new section
* make sure the definition of genetic and genomic tests in the glossary is consistant
** incorporate definition from SACGHS report; also "Where there's a web, there's a way" paper
** like pharmacogenetics vs. pharmacogenomics?
* visit http://www.egappreviews.org/workingrp/topics_consider.htm
* visit http://www.cdc.gov/genomics/gtesting/
== 11 Jan 2010 ==
[[/11-Jan-2010|Notes]]
<strike>
* Got [http://www.genome.duke.edu/people/faculty/angrist/ Misha's] Feedback
** read this: [http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlt&cntvwrPtlt{actionForm.contentReference}=committees%2Ftechnology%2Fivdmia.html&_state=maximized&_pageLabel=cntvwr College of American Pathologists POET report on IVDMIAs]
** And this: [http://www.insightpharmareports.com/Reports_report.aspx?id=71450&r=555 market report w/r/t multivariate testing] (at least the table of contents)
* [[Mac/Agenda/2-Dec-2009#Reference_Labs_market_data|Get Annual Reports from key companies listed; summarize]]
* Add papers about [[Diagnostic_Kits/Commons_based_cases_in_Kits#GDx_Reference_Materials | GDx reference materials from Journal of Molecular Diagnostics]]
* add profiles of major Personal Genomics companies to [[Diagnostic_Kits/Give_an_overall_picture_of_the_Kits'_sector#major_companies_in_Personal_Genomics_industry | Overall Picture of Kits Sector]]
</strike>
== 2 Dec 2009 TODO ==
== 2 Dec 2009 TODO ==
[[Mac/Agenda/2-Dec-2009|Notes]]
* add GDx / PGx  from SACGHS appendix and PGx paper to the case studies (~15?)
* add GDx / PGx  from SACGHS appendix and PGx paper to the case studies (~15?)
** Add OTC genetic tests to the list
** Add OTC genetic tests to the list
Line 5: Line 42:


* write 1 paragraph / section of paper outline
* write 1 paragraph / section of paper outline
* centralize answers to "do patents harm researchers?"
* centralize answers to "do patents harm researchers?"
* complete [[Talk:Diagnostic_Kits#Field_Definition| field definition]]
 
* complete data, narratives, tools defn, build off of Ford report section
* <strike>complete [[Talk:Diagnostic_Kits#Field_Definition| field definition]]</strike> - 1st draft
** get basic market stats / picture (just GDx)
** <strike>complete data, narratives, tools defn, build off of Ford report section</strike>
*** <strike>get basic market stats / picture (just GDx)</strike> - partial; just national ref labs
 
* read last chapter's of Gene Cartels
* read last chapter's of Gene Cartels
* read SACGHS Report final draft
* <strike> [[SACGHS_Appendix_1-_Compendium_of_Case_Studies_on_the_Impact_of_Gene_Patents_and_Licensing_Practices_on_Access_to_Genetic_Testing| read SACGHS Report final draft]] </strike>
* back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.")
* back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.")
** http://cyber.law.harvard.edu/commonsbasedresearch/?title=Diagnostic_Kits/The_Argument_Framework&direction=next&oldid=4910
** http://cyber.law.harvard.edu/commonsbasedresearch/?title=Diagnostic_Kits/The_Argument_Framework&direction=next&oldid=4910

Latest revision as of 13:53, 27 January 2010

18 Jan 2010

Notes

  • read a bunch of other papers I printed
  • compress the findings of the SACGHS report, European report, and Australian report in an executive summary in new section
  • make sure the definition of genetic and genomic tests in the glossary is consistant
    • incorporate definition from SACGHS report; also "Where there's a web, there's a way" paper
    • like pharmacogenetics vs. pharmacogenomics?
  • visit http://www.egappreviews.org/workingrp/topics_consider.htm
  • visit http://www.cdc.gov/genomics/gtesting/

11 Jan 2010

Notes

2 Dec 2009 TODO

Notes

  • add GDx / PGx from SACGHS appendix and PGx paper to the case studies (~15?)
    • Add OTC genetic tests to the list
    • move to no.2, overall picture of kits
  • write 1 paragraph / section of paper outline
  • centralize answers to "do patents harm researchers?"
  • complete field definition - 1st draft
    • complete data, narratives, tools defn, build off of Ford report section
      • get basic market stats / picture (just GDx) - partial; just national ref labs

Duke team, Luigi interview

  • come up w/ questions
  • position on IVDMIAs
  • use interview framework from EM

Identify people to ask about IVDMIA tests

  • look at federal docket of comments in response to draft guideline
  • ask the 5 OTC companies in interview